BRILLIANT II

BRILLIANT II

A trial which was to test the clinical performance of the batimastat-loaded stent relative to a PC Technology™ stent without the drug, and to be conducted at centres in the UK, France, Belgium and Holland. Review of the data from BRILLIANT I did not show the benefit that was evident in the pre-clinical studies, and led to suspension of patient recruitment for BRILLIANT II.
Mentioned in ?
References in periodicals archive ?
Biocompatibles (LSE: BII) and British Biotech (LSE: BBG, NASDAQ: BBIOY) announced today that recruitment in BRILLIANT II, the double-blind pivotal clinical trial designed to secure CE Mark Approval for the Batismastat BiodivYsio(R) stent in Europe, has been suspended pending review of further data from the BRILLIANT I clinical trial.